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Abstract: Rabies is a fatal encephalitis caused by an important group of viruses within the Lyssavirus
genus. The prototype virus, rabies virus, is still the most commonly reported lyssavirus and causes ap-
proximately 59,000 human fatalities annually. The human and animal burden of the other lyssavirus
species is undefined. The original reports for the novel lyssavirus, Kotalahti bat lyssavirus (KBLV),
were based on the detection of viral RNA alone. In this report we describe the successful genera-
tion of a live recombinant virus, cSN-KBLV; where the full-length genome clone of RABV vaccine
strain, SAD-B19, was constructed with the glycoprotein of KBLV. Subsequent in vitro characterisa-
tion of cSN-KBLV is described here. In addition, the ability of a human rabies vaccine to confer
protective immunity in vivo following challenge with this recombinant virus was assessed. Naïve
or vaccinated mice were infected intracerebrally with a dose of 100 focus-forming units/30 µL of
cSN-KBLV; all naïve mice and 8% (n = 1/12) of the vaccinated mice succumbed to the challenge,
whilst 92% (n = 11/12) of the vaccinated mice survived to the end of the experiment. This report
provides strong evidence for cross-neutralisation and cross-protection of cSN-KBLV using purified
Vero cell rabies vaccine.
Keywords: rabies; lyssavirus; Kotalahti bat lyssavirus; KBLV; bats; vaccine protection; neutralisation;
emerging; novel; zoonoses
1. Introduction
Rabies is caused by viruses classified within the Lyssavirus genus, family Rhabdoviri-
dae, order Mononegavirales [1]. These viruses are of importance to both human and
animal health given the invariably fatal outcome from developing a neurological dis-
ease [2]. The genus Lyssavirus is divided into 17 species accepted by the International
Committee on the Taxonomy of Viruses (ICTV) with two tentative novel lyssaviruses, Kota-
lahti bat lyssavirus (KBLV) and Matlo bat lyssavirus (MBLV), awaiting classification [3–5].
The ancestral lyssavirus reservoir host species is universally accepted as being members
of the order Chiroptera with all but two lyssaviruses, Mokola and Ikoma lyssaviruses,
having been detected in different bat species [6–8]. As well as lyssaviruses, bats have been
associated as the host reservoir for an abundance of viruses, including coronaviruses (SARS
and MERS viruses), filoviruses (Marburg virus and the newly discovered Měnglà virus),
and Henipaviruses [9–11].
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Within the Lyssavirus genus, the most broadly distributed and important to veterinary
and public health is the rabies virus (RABV). Though this virus has largely been eliminated
throughout western Europe, RABV is still the most commonly reported lyssavirus. RABV
causes approximately 59,000 human deaths annually with the majority of these fatalities
(>99%) being associated with dog-mediated transmission [12]. The human and animal
burden of the other lyssaviruses, however, is largely undefined, with only 14 human
lyssavirus-related deaths being reported [13,14]. This low number of reported cases may
be because diagnostic capabilities often reliant on antigen detection or a clinical diagno-
sis, particularly in endemic areas, are unable to distinguish between different lyssavirus
species [13,15].
The negative-stranded RNA lyssavirus genome consists of five genes that encode the
nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and viral
RNA polymerase (L). Within the Lyssavirus genus, the species are genetically categorised
according to the homology of nucleotide sequence encoding N and have been proposed
to form distinct phylogroups following a combination of genetic and antigenic assess-
ment [16,17]. Currently, rabies vaccines marketed for human use are based on whole
inactivated RABV particles. It is understood that rabies vaccines confer protective immu-
nity against phylogroup I lyssaviruses, which includes classical RABVs, Australian bat
lyssavirus (ABLV), Aravan virus (ARAV), Bokeloh bat lyssavirus (BBLV), Duvenhage virus
(DUVV), European bat lyssavirus type 1 (EBLV-1), European bat lyssavirus type 2 (EBLV-2),
Gannoruwa bat lyssavirus (GBLV), Irkut virus (IRKV), and Khujand virus (KHUV) [18–20].
Certainly, studies undertaken have indicated that the level of protective immunity afforded
by current vaccines against phylogroup I lyssaviruses correlate to the antibody titre level
induced in the recipient of the vaccine. An antibody titre of 0.5 IU/mL is generally consid-
ered a conservative threshold above which protection from classical rabies virus strains
is likely [21]. However, it has been suggested that a higher neutralising antibody titre is
required to confer protection against non-RABV phylogroup I lyssaviruses [22]. Current ev-
idence from an in vivo study suggested that an antibody titre of ≥10 IU/mL is required for
protection against BBLV whilst in vitro ≥4.5 IU/mL is required for complete neutralisation
of EBLV-1, EBLV-2, and ABLV [18,23]. Nevertheless, a defined cut-off for protection against
non-RABV phylogroup I lyssaviruses remains to be established. Conversely, current RABV
vaccines elicit no level of protective immunity against the more divergent lyssaviruses in
phylogroup II, which includes Lagos bat virus (LBV Lineages A–D), Mokola virus (MOKV),
and Shimoni bat virus (SHIBV), as well as highly divergent viruses tentatively assigned to a
third phylogroup, which includes Ikoma lyssavirus (IKOV), Lleida bat lyssavirus (LLEBV),
and West Caucasian bat virus (WCBV) [24–26].
Whilst RABV is the most commonly reported lyssavirus in terrestrial species, the
epidemiology of non-RABV lyssaviruses is less well understood. ARAV, KHUV, SHIBV,
and IKOV, specifically, exist as single detections. Consequently, gaps in epidemiological
distribution, host range, and ability to cross the species barrier remain. The continual
discovery of novel lyssaviruses in bats has warranted an increasing interest in the degree
of vaccine cross-protection afforded by rabies vaccines [13].
In 2017, nucleic acid from a novel lyssavirus, termed Kotalahti bat lyssavirus (KBLV),
was discovered in a Brandt’s bat (Myotis brandtii) in Kotalahti, Finland [27]. Attempts to
isolate the virus were unsuccessful, likely because the bat was in a considerable stage of
decomposition on arrival to the Finnish Food Safety Authority Evira [27]. Initial genetic
assessment enabled amplification of a small fragment of the genome and sequencing of the
nucleoprotein encoding gene demonstrated that KBLV was most closely related to KHUV
(81%), followed by ARAV (79.7%), BBLV (79.5%), and EBLV-2 (79.4%), at the nucleotide
level [27]. A follow-up investigation using deep sequencing successfully obtained the
full KBLV genome sequence consisting of 11,878 nucleotides encoding for the five genes
N, P, M, G, and L. Consequently, it was determined that KBLV is phylogenetically more
closely related to EBLV-2 and clusters with KHUV and BBLV [4]. It was also determined
that sera, derived from humans vaccinated against RABV, demonstrated cross-neutralising
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activity against KBLV G pseudotyped RABV particles [4]. Despite the preliminary findings,
attempts to isolate a live replication competent KBLV virus or recombinant virus were
unsuccessful. This has prevented the in vivo evaluation of vaccine efficacy as well as full
antigenic characterization.
The lyssavirus glycoprotein (G) is the only viral surface protein and is the sole target for
neutralising antibodies [28]. Previous studies have utilised reverse genetics (RG) techniques
to exchange G proteins derived from other lyssavirus species into a RABV vaccine RG
backbone to enable assessment of vaccine protection against recombinant viruses [29–31].
The present study describes the development of a live recombinant RABV where the
RABV G has been replaced by KBLV G. In vitro and in vivo studies were used to define the
ability of vaccine-derived sera and vaccine-induced antibodies (anti-RABV) to neutralise
and protect against a recombinant virus containing the KBLV G protein in a murine model.
2. Materials and Methods
2.1. Cells
BHK-21 (BHK) cells were propagated in Glasgow’s modified Eagle’s medium (GMEM;
Gibco, Loughborough, UK) supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL
streptomycin and 25 U/mL mycostatin (Invitrogen, Paisley, UK). BSR-T7/5 cells (BHK-
derived cells that stably express T7 RNA polymerase—a kind gift from Dr Stefan Finke, FLI,
Greifswald, Germany) were propagated in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco) supplemented with 5–10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, and
25 U/mL mycostatin (Invitrogen).
2.2. Full-Length Plasmid Construction
The cDNA clone of the SN strain of RABV (cSN) was derived from the SAD B19 cDNA
clone as described previously [28,32,33]. Subsequently, cSN was used as a DNA backbone
vector for the assembly of the recombinant virus by exchanging cSN RABV G with KBLV
G through the process of Gibson assembly (New England Biolabs (NEB), Hitchin, UK) [34].
The KBLV G open reading frame (ORF) (European Nucleotide Archive accession no. PR-
JEB41152) was amplified with 20 bp overhangs directed at the 5′ and 3′ end of cSN using the
Q5® Hot Start High-Fidelity 2X Master Mix (NEB) and the following primers: KBLVFwd
(5′-CTCAAAAGACCCCGGGAAAGATGCCATTTCAAGCGGTTC-3′) and KBLVRev (5′-
GTTGAAAGGCTAGCCAGTCCCTAGGCCTGAGACTGATC-3′). The underlined sequences
within the primers are the incorporated overhangs complementary to cSN. To generate
a linear cSN lacking the RABV G, the following primers and the same PCR master mix
were used: cSNFwd (5′-GGACTGGCTAGCCTTTCAAC-3′) and cSNrev
(5′-CTTTCCCGGGGTCTTTTG-3′).To confirm the presence of PCR amplicons of the ap-
propriate size, reaction products were assessed via agarose gel electrophoresis. The insert
and vector PCR products were purified using the Monarch® PCR & DNA Cleanup Kit
(NEB). Dpn1 (NEB) digestion was performed on the purified PCR products to remove
residual vector DNA prior to recombinant genome assembly of the insert (KBLV G) and
vector (cSN) DNA using the NEBuilder® HiFi DNA Assembly Cloning Kit (NEB). Follow-
ing transformation, plasmid propagation and plasmid harvest, plasmids were sequenced
before virus rescue was attempted.
2.3. Virus Rescue and Titration
Virus rescue for cSN-KBLV was undertaken as described previously [30,31]. Briefly,
BSR-T7/5 cells were seeded at 3 × 104 cells per well in a 96-well plate (Corning, High
Wycombe, UK) 18 h before transfection and 200 ng of the full-length genome plasmid
and 40 ng of each of three helper plasmids, encoding the RABV N, P, and L proteins, were
transfected into cells using the FuGENE®6 Transfection Reagent (Promega, Southampton,
UK). Transfected cells were then passaged with fresh BSR-T7/5 cells at a 1:1 ratio in a
12-well plate following a 72–96 h incubation at 37 ◦C. Further passage was undertaken,
and cells were assessed for virus antigen as described previously [35]. Where virus antigen
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was detected, supernatant was aspirated off and passaged further in BHK cells until 100%
infection of the cell monolayer was achieved. Final stocks of cSN-KBLV were sequenced in
their entirety using whole genome sequencing to confirm the expected sequence.
2.4. Virus Titration and Growth Kinetics
Virus titre was determined in triplicate in BHK cells as previously described [32]. Cells
were seeded at 3 × 105 cells per well and infected with virus serially diluted 10-fold in a 96-
well plate (Corning). Cells were fixed with 80% acetone and stained with FITC anti-rabies
monoclonal globulin (Fujirebio, Tokyo, Japan) at 48 h post-infection (hpi). Fluorescent foci
were counted and recorded as fluorescent focus forming units per mL (ffu/mL).
Virus growth for cSN-KBLV was assessed using a multistep growth curve in compari-
son with the parent virus cSN as described previously [30]. Cells were then infected with
each virus at a multiplicity of infection (moi) of 0.1 and at set time points (0 h, 6 h, 12 h, 24 h,
48 h, 72 h, 96 h, 120 h) 150 µL of media was removed and frozen at −80 ◦C until required.
After the course of the experiment, each of the time point aliquots were titrated in triplicate
on fresh BHK cells as three independent titration experiments. Titres were compared using
the Mann–Whitney test.
2.5. In Vitro Studies
To assess cross-neutralisation, a modified version of the fluorescent antibody virus neu-
tralisation test (mFAVN) was used as described previously [36,37]. Excluding cSN-KBLV, a
panel of 12 lyssaviruses (Table 1) and a panel of polyclonal antisera raised against 9 viruses
was used to assess cross-neutralisation. Three RABV isolates were used for comparison; a
wild or street RABV isolate (designated RABV in this study), the rabies challenge standard
virus-11 isolate (designated CVS in this study), and the RABV parent virus isolate used as
the backbone for cSN-KBLV (designated cSN in this study). Where standardised control
sera were required, the following three RABV-specific polyclonal sera were used: WHO
serum, OIE serum, and hyperimmune human sera from a Human diploid cell vaccine
(HDCV) (Rabies Vaccine BP; Pasteur Merieux, Lyon, France) recipient. There are no inter-
nationally agreed cut-offs for interpreting neutralising antibody titres against lyssaviruses
other than CVS. As a result, for mFAVN, a threshold (reciprocal titre of 1:16) was chosen by
comparison with standard sera (0.5 IU/mL) that exhibits a similar titre against CVS.
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RABV RABV Yes 1.6 × 105 RV437 Raccoon dog - Estonia KF154997 [38]
CVS RABV No 4.3 × 106 Challenge virus standard-11 strain EU352767 [39]
cSN RABV No 1.2 × 106 Recombinant virus; Street Alabama Dufferin (SADB19) backbone + SADB19glycoprotein M31046
ˆ [40]
ABLV ABLV Yes 1.5 × 105 RV634 Bat 1996 Australia AY062067(G) [41]
ARAV ARAV Yes 2.0 × 105 RV3379 Bat 1991 Kyrgyzstan EF614259 [42]
BBLV BBLV Yes 2.5 × 106 RV2507 Bat 2009 Germany JF311903 [43]
DUVV DUVV Yes 3.0 × 106 RV131 Bat 1986 Zimbabwe GU936870(G) [37]
EBLV-1 EBLV-1 Yes 4.0 × 106 RV20 Bat 1986 Denmark KF155003 [38]
EBLV-2 EBLV-2 Yes 4.3 × 104 RV628 Bat 1996 UK KY688136 [44]
GBLV GBLV Yes 4.0 × 105 RV3267 Bat 2015 Sri Lanka KU244267 [45]
IRKV IRKV No 1.8 × 105 RV3382 Bat 2002 Siberia EF614260 [46]
KHUV KHUV Yes 5.0 × 104 RV3380 Bat 2001 Tajikistan EF614261 [42]
Abbreviations: ABLV, Australian bat lyssavirus; ARAV, Aravan virus; BBLV, Bokeloh bat lyssavirus; DUVV, Duvenhage virus; EBLV, European bat lyssavirus; GBLV, Gannoruwa bat lyssavirus; IRKV, Irkut virus; KHUV,
Khujand virus; RABV, rabies virus. * Animal and Plant Health Agency lab identification number. $ Where full genome sequence accession numbers cannot be found, glycoprotein sequence accession numbers have been
included instead and are highlighted by (G). ˆ SADB19 GenBank accession number. - Data not known.
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2.6. In Vivo Studies
All in vivo experimentation was undertaken in ACDP3/SAPO4 biocontainment fa-
cilities at the Animal and Plant Health Agency (APHA), Weybridge, UK, and complied
with strict UK Home Office regulations under the Animals in Scientific Procedures Act
(1986) and Home Office license PCA17EA73. Three-to-four-week-old female BALB/c mice
were purchased from a commercial supplier (Charles River, Margate, UK). Mice (n = 12)
were vaccinated with 0.5 mL of diluted human rabies vaccine VeroRab (Novartis, Sur-
rey, UK) via the intraperitoneal (ip) route at days 0 and 7. Mock-vaccinated mice (n = 8)
were inoculated with MEM alone via ip. At day 29 post-vaccination, both the vaccinated
and mock-vaccinated mice were challenged intracranially (ic) with 100 ffu/30 µL of cSN-
KBLV. Following virus challenge, mice were observed twice daily for 22 days and clinical
signs were scored using a scale of 0–5 (where 0, no effect; 1, hunched body/ruffled fur;
2, limb twitching; 3, hindquarter paralysis; 4, progressive paralysis; 5, terminal recum-
bency/death) [47]. The humane endpoint for termination was a clinical score of 1–2 where
mice were bled under terminal anaesthesia followed by cervical dislocation. Kaplan–Meier
survival curves and the log-rank Mantel–Cox test were used to analyse survivorship rates.
2.7. Virus Detection
A fluorescent antibody test (FAT) was undertaken as described previously [48]. Briefly,
brain tissue was excised from the cerebellum and two impression smears were made on a
microscope slide. Slides were left to air dry for 5 minutes at room temperature before being
fixed in 99–100% acetone, washed, rinsed, and stained using FITC anti-rabies monoclonal
globulin (Fujirebio, 800-092). Fluorescent green foci would indicate the presence of the N
protein thereby indicating virus infection. Positive control material consisted of previously
extracted CVS-infected mouse brain. Two mice from each group were tested.
Histopathology and immunohistochemistry were performed as described previ-
ously [49]. Mouse carcasses were fixed in 10% neutral buffered formalin for 2 weeks
before being sectioned coronally and processed into paraffin tissue blocks. Serial sections of
4 µm were prepared and stained with haematoxylin and eosin (H&E) for histopathology or
immunohistochemistry for rabies virus nucleoprotein using a monoclonal antibody, mAb
5B12 (MyBioSource Inc., San Diego, CA, USA).
2.8. Molecular Analyses
A real-time SYBR based reverse transcription PCR (RT-PCR) assay (Bio-Rad, Hemel
Hemstead, UK) was used to determine the presence or absence of lyssavirus RNA in the
mouse samples. Nucleic acids were extracted from brain tissue using Trizol (Invitrogen)
according to manufacturer’s instructions. A SYBR real-time RT-PCR with N gene-specific
primers and 1µg/µL of RNA was undertaken as described previously [50,51]. For semi-
quantitative assessment of viral RNA, cDNA of CVS, at a known concentration (copies/g),
was serially diluted from 10−1 to 10−8 in nuclease-free water and used alongside the mouse
brain RNA extracts as a standard curve on the real-time RT-PCR assay. This standard
curve was used to semi-quantitate the presence of viral RNA in each sample tested by
comparison across Ct values. Amplification using beta actin-specific primers was used as a
control for RNA extraction as described previously [51]. Two mice from each group were
tested in triplicate.
2.9. Serology
The dorsal vein of each mouse was nicked and blood was collected in CB300 blood
collection tubes with clotting activator (Sarstedt, Leicester, UK) at 21 days post-vaccination
to assess seroconversion to the VeroRab vaccine. Each serum sample was tested with a
standard fluorescent antibody virus neutralisation (FAVN) test as described previously [52].
At the termination of the experiment, mice were cardiac bled under terminal anesthesia and
sera were assessed by FAVN against CVS and modified FAVN against cSN-KBLV. Virus-
Viruses 2021, 13, 947 7 of 21
neutralising antibody titres were compared by two-way ANOVA and Tukey’s multiple
comparisons tests.
2.10. Antigenic Cartography
Lyssavirus antigenic maps were generated from the mFAVN data as described previ-
ously [37,53]. To optimise the relative positions of the viruses and sera on a map, metric and
ordinal multidimensional scaling techniques were used. Where neutralisation occurred,
each virus was positioned by multiple sera and vice versa. Hence, antisera with different
neutralisation profiles to the homologous viruses could be in separate locations on the map
but still contribute to the positioning of the viruses. Whilst resolution increased with each
increasing dimension, 3D maps were used to determine antigenic distance and visualisation
as the incremental increase in precision became negligible beyond three dimensions [37].
For highlighting antigenic clusters, 2D maps were included for clarity.
2.11. Phylogenetics
Phylograms were constructed in MEGA6 using the neighbour-joining (NJ) algorithm
after sequences were aligned. The sequences were bootstrap re-sampled 1000 times to assess
the robustness of each tree node. The evolutionary distances were computed using the max-
imum composite likelihood method and measured in the units of the number of base sub-
stitutions per site. The resulting tree was viewed in FigTree v1.4.2 (University of Edinburgh,
Edinburgh, UK; http://tree.bio.ed.ac.uk/software/figtree/ (accessed on 20 March 2021)).
3. Results
3.1. Virus Rescue and Titration
The cSN-KBLV virus was successfully rescued using RABV helper plasmids. After
5 passages, cSN-KBLV reached 100% infectivity whilst cSN only required 2 passages.
Following the final passage to achieve 100% infectivity, the virus was harvested and
subsequent whole genome sequencing confirmed 100% nucleotide identity to the original
DNA cSN-KBLV clone (data not shown). Harvested virus was titrated in which the cSN-
KBLV grew to a peak titre of 2.5 × 104 ffu/mL whilst the parent cSN strain grew to a peak
titre of 1.6 × 106 ffu/mL. Both values, however, are comparable to similar studies using
EBLV-1, EBLV-2 G, IKOV G, and WCBV G within a cSN vector [30,31].
3.2. Growth Kinetics
Due to the fact that the wildtype virus for KBLV had not been successfully isolated [4],
the growth kinetics of cSN-KBLV were compared to that of cSN using multistep growth
curves (Figure 1). By 24 hpi, both viruses were detected at around 103 ffu/mL. There was
no statistically significant difference between the peak viral titres observed, however, cSN
grew to the highest peak titre of 7.6 × 107 ffu/mL at around 96 hpi and cSN-KBLV grew
to a peak titre of 1.55 × 107 ffu/mL at 72 hpi. The endpoint titres showed a sigificant
difference between the two viruses with cSN-KBLV exhibiting a titre of 3.33 × 106 ffu/mL
compared to cSN at 4.3 × 107 ffu/mL (p < 0.001).
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Figure 1. Growth kinetics of cSN-KBLV and the vaccine backbone, cSN, in vitro. For each virus, 
BHK-21 cells were infected with an MOI of 0.1 to produce a multiple-step growth curve over the 
course of 120 h. The test was performed in triplicate and the mean and standard deviation of the 
results plotted on a logarithmic scale. Asterisks indicate significant differences between the groups 
calculated using the Mann–Whitney test (*** p < 0.001). 
3.3. In Vitro Studies 
Two experimental approaches were taken to assess cSN-KBLV antigenically: (i) to 
determine the titre of standard sera sufficient to neutralise cSN-KBLV over the 0.5 IU/mL 
value assigned as the cut-off for protection, and (ii) to evaluate for cross-neutralisation 
across the lyssavirus genus. 
3.3.1. Assessment of cSN-KBLV Neutralisation Using Internationally Standardised Sera 
A modified FAVN was used to test the comparative neutralisation of cSN-KBLV, cSN 
and CVS against increasing titres of two standard sera, OIE and WHO. Both the OIE and 
WHO sera were capable of neutralising all three viruses at 1 IU/mL and at 2.5 IU/mL, 
respectively (Figure 2). Both CVS and cSN were neutralised by both OIE and WHO sera 
with complete neutralisation at 0.5 IU/mL. Both serological standards demonstrated the 
lowest level of neutralising antibodies against cSN-KBLV as 1 IU/mL of OIE sera and 2.5 
IU/mL of WHO sera were required to neutralise cSN-KBLV to above the 0.5 IU/mL thresh-
old for WHO and OIE sera against CVS. Additionally, the trend in neutralising antibody 
levels differed between each of the standard sera used. 
OIE sera consistently showed higher levels of neutralising antibodies than WHO sera 
when tested against each of the viruses, though the greatest difference was observed with 
cSN-KBLV. At 5 IU/mL, OIE sera showed almost a 10-fold increase in neutralising anti-
body titre against cSN-KBLV than the WHO sera, and almost double for CVS and cSN. 
Figure 1. Growth kinetics of cSN-KBLV and the vaccine backbone, cSN, in vitro. For each virus,
BHK-21 cells were infected with an MOI of 0.1 to produce a multiple-step growth curve over the
course of 120 h. The test was performed in triplicate and the mean and standard deviation of the
results plo ted on a logarithmic scale. Asterisks indicate significant differences betw en the groups
calculated using the Ma n–Whitney test ( * p < 0. 01).
3.3. In Vitro Studies
Two experimental approaches were taken to assess cSN-KBLV antigenically: (i) to
determine the titre of standard sera sufficient to neutralise cSN-KBLV over the 0.5 IU/mL
value assigned as the cut-off for protection, and (ii) to evaluate for cross-neutralisation
across the lyssavirus genus.
3.3.1. Assessment of cSN-KBLV Neutralisation Using Internationally Standardised Sera
A modified FAVN was used to test the comparative neutralisation of cSN-KBLV, cSN
and CVS against increasing titres of two standard sera, OIE and WHO. Both the OIE and
WHO sera were capable of neutralising all three viruses at 1 IU/mL and at 2.5 IU/mL,
respectively (Figure 2). Both CVS and cSN were neutralised by both OIE and WHO sera
with complete neutralisation at 0.5 IU/mL. Both serological standards demonstrated the
lowest level of neutralising antibodies against cSN-KBLV as 1 IU/mL of OIE sera and
2.5 IU/mL of WHO sera were required to neutralise cSN-KBLV to above the 0.5 IU/mL
threshold for WHO and OIE sera against CVS. Additionally, the trend in neutralising
antibody levels differed between each of the standard sera used.
OIE sera consistently showed higher levels of neutralising antibodies than WHO sera
when tested against each of the viruses, though the greatest difference was observed with
cSN-KBLV. At 5 IU/mL, OIE sera showed almost a 10-fold increase in neutralising antibody
titre against cSN-KBLV than the WHO sera, and almost double for CVS and cSN.
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Figure 2. Neutralisation profiles of cSN-KBLV, cSN, and CVS against OIE and WHO standard sera using a modified flu-
orescent antibody virus neutralisation (mFAVN) test. The test was performed in triplicate and the mean and standard 
deviation of the results plotted on a logarithmic scale. The 0.5 IU/mL neutralisation cut-off is dictated by the serological 
standards against CVS (indicated by the coloured dashed lines—OIE = blue, WHO = purple). 
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Figure 2. Neutralisation profiles of cSN-KBLV, cSN, and CVS against OIE and WHO standard sera using a modified
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deviation of the results plotted on a logarithmic scale. The 0.5 IU/mL neutralisation cut-off is dictated by the serological
sta ar s a ai st S (i icate t e c l re as e li es I l e, r le).
3.3.2. Ability of Phylogroup I-Specific Sera to Neutralise cSN-KBLV
A mFAVN was used to assess cross-neutralisation of lyssavirus-specific sera against
cSN-KBLV in addition to CVS and cSN as comparison (Figure 3). Varying levels of cross-
neutralisation were observed with phylogroup I lyssavirus-specific sera described in
Table 1. The virus cSN was most readily neutralised by the phylogroup I sera panel with
seven lyssavirus-specific sera showing levels of neutralising antibodies above 0.5 IU/mL
whereas cSN-KBLV and CVS were neutralised by five lyssavirus-specific sera. For cSN-
KBLV, ARAV, BBLV, EBLV-1, EBLV-2, and GBLV-specific sera exhibited a titre of neutralising
antibodies above the 0.5 IU/mL cut-off whilst ABLV, DUVV, KHUV, and RABV-specific
sera did not. In addition, the ability of each sera to cross-neutralise each virus varied. For
cSN-KBLV, EBLV-1-specific sera showed the highest titre of neutralising antibodies. BBLV-
specific sera exhibited the greatest titre of neutralising antibodies against CVS. Specific sera
for a wild/street RABV strain showed the highest titre of neutralising antibodies against
cSN, closely followed by BBLV and EBLV-1. Interestingly, the wild/street RABV-specific
sera were only capable of neutralising cSN, indicating possible antigenic divergence of
wild/street strains to the cell culture-adapted CVS used regularly in diagnostic assays.
Phylogroup II-specific sera were unable to neutralise all three viruses tested (data not
shown) nd IRKV-specific sera were unavailable.
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3.3.3. Antigenic Cartography
Antigenic cartography was used to quantify antigenic relationships between phy-
logroup I viruses described in Table 1 and enable comparison to the evolutionary relation-
ships facilitated via phylogenetic nucleotide analysis (Figure 4). Results showed cSN-KBLV
was antigenically distinct from the other phylogroup I lyssaviruses, including the parent
virus, cSN (Figure 4A,C,D). Based on the antigenic distances on the 3D map, cSN-KBLV is
antigenically closest to cSN (1.00 AU), ARAV (1.21 AU), IRKV (1.45 AU), and EBLV-2 (1.65
AU). To further investigate the genetic basis of the antigenic distances, the evolutionary
history of the glycoprotein nucleotide sequences of each phylogroup I lyssavirus was
quantitatively inferred using the neighbour-joining method and the evolutionary distances
were computed using the maximum composite likelihood (ML) method and displayed as a
phylogenetic tree (Figure 4B). Based on the glycoprotein evolutionary distances, KBLV is
most closely related to EBLV-2, KHUV, and BBLV. The correlation between antigenic dis-
tance and ML phylogenetic tree distance could be inferred by comparing the evolutionary
and antigenic distances between cSN and each of the viruses. Based on this data, 1 AU was
equal to an ML distance of 0.235 (p = 0.007) when RABV and CVS were excluded from the
dataset. This was due to the fact that RABV G and CVS G are highly genetically similar
to cSN G but re antigenically distinct, highlighting that it is not always possible to infer
antigenic distance based on etic d ta alone.
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3.4. In Vivo Vaccination Challenge Study
3.4.1. Vaccination and Survival
To assess the ability of vaccine-induced neutralising antibodies to protect mice from
challenge with cSN-KBLV, mice were vaccinated as described and a standard FAVN test
was used to determine serological response. All mice seroconverted to a titre above the
internationally assigned cut-off for neutralisation of RABV, 0.5 IU/mL, with responses
ranging from 0.87 IU/mL to 23.38 IU/mL 21 days after vaccination (Figure 5A). Mice were
challenged via the ic route on day 29 post-vaccination with 100 ffu/30 µL of cSN-KBLV
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and clinical outcomes were compared to mock-vaccinated mice challenged with the same
dose of cSN-KBLV. A statistically significant difference (p < 0.001) in survival was observed
between the vaccinated and mock-vaccinated groups (Figure 5B). All mice in the mock-
vaccinated group (n = 8) reached clinical endpoint by 7 days post-challenge, 1 day after
onset of clinical disease. The first sign of clinical disease was ruffled fur. Subsequent clinical
signs observed included piloerection, tail-biting, intermittent hyperactivity, and hunched
stance. In the vaccinated group (n = 12), one mouse was terminated after developing score
2 clinical signs, which included an extreme hunched stance and limb twitching. The time
from initiation of disease to termination in line with humane endpoints was protracted,
however, with the mouse reaching clinical endpoint at day 13 post-challenge, 3 days after
the onset of clinical disease. In addition, the vaccinated mouse that succumbed to infection
had the lowest neutralising antibody titre of 0.87 IU/mL prior to challenge (indicated by H
on the graph). In contrast, all mice with virus-neutralising antibody titres of 1.5 IU/mL
and above survived the challenge.
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All animals that succumbed to clinical disease or survived until the end of the exper-
iment were cardiac bled before being humanely terminated. Sera were assessed for sero-
conversion using both the standard FAVN against CVS and modified FAVN against cSN-
KBLV. In the mock-vaccinated group (n = 8), 63% (n = 5/8) of the animals had an antibody 
response capable of neutralising cSN-KBLV using the modified FAVN. Of the mouse sera 
that exhibited neutralising antibodies against cSN-KBLV, the reciprocal titres ranged from 
1/16 to 1/421. In contrast, no neutralising antibody against CVS was detected with the 
standard FAVN (Figure 6). Despite the difference in mean reciprocal titres against CVS in 
the standard FAVN (1/4 ± 1/2) and cSN-KBLV in the modified FAVN (1/87 ± 1/134), the 
difference was not statistically significant (p = 0.066). 
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the antibody titre (IU/mL) and the Y2 axis represents the equivalent reciprocal antibody titre. (B) In vivo surviv rship
following intracranial inoculation with 100 ffu/30 µL of cSN-KBLV. Mice were vaccinated 28 days before challenge and day
0 on the graph refers to the day of challenge.
3.4.2. Serological Responses to Infection and Post-Vaccination Challenge
All animals that succumbed to clinical disease or survived until the end of the ex-
periment were cardiac bled before being humanely terminate . Sera were assessed for
seroconversion using both the standard FAVN against CVS and modified FAVN against
cSN-KBLV. In the mock-vaccinated group (n = 8), 63% (n = 5/8) of the animals had an anti-
body response capable of neutralising cSN-KBLV using the modified FAVN. Of the mouse
sera that exhibited neutralising antibodies against cSN-KBLV, the reciprocal titres ranged
from 1/16 to 1/421. In contrast, no neutralising antibody against CVS was detected with
the standard FAVN (Figure 6). Despite the difference in mean reciprocal titres against CVS
in the standard FAVN (1/4 ± 1/2) and cSN-KBLV in the modified FAVN (1/87 ± 1/134),
the difference was not statistically significant (p = 0.066).
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KBLV-challenged mice were serologically assessed against CVS and cSN-KBLV using FAVN and 
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cate significant differences between the groups calculated using an ordinary two-way ANOVA 
and Tukey’s multiple comparisons tests (*** p < 0.001; ns is not significant). 
For the vaccinated group, all surviving mice developed neutralising antibody titres. 
In the standard FAVN against CVS, sera showed neutralising antibody titres ranging from 
1/243 to 1/59049. In the modified FAVN against cSN-KBLV, sera showed less variability 
with neutralising antibody titres ranging from 1/729 to 1/34092. On average, however, the 
titre of neutralising antibodies against CVS and cSN-KBLV were not significantly differ-
ent. 
When comparing the serology post-challenge to that following vaccination and prior 
to challenge (using the standard FAVN), the titre of neutralising antibodies in the vac-
cinated group increased 50-fold from an average reciprocal titre of 1/284 to 1/14400 (Fig-
ures 5 and 6). 
Interestingly, the one mouse that succumbed to infection on day 13 post-infection 
showed high reciprocal titres of 1/1262 against CVS and 1/2187 against cSN-KBLV (as in-
dicated by  in both Figures 5A and 6). Despite this, sera from the vaccinated group show 
a statically significant difference in neutralising antibody titres against CVS and cSN-
KBLV than the sera derived from the mock-vaccinated group (p < 0.001). 
3.4.3. Histopathology and Immunohistochemistry 
Of the mice that succumbed to cSN-KBLV, two were tested on the FAT and were 
positive for viral antigen. In contrast, of the mice that were vaccinated and survived chal-
lenge with cSN-KBLV, two were tested on the FAT and were all negative (data not 
shown). To demonstrate the pathogenicity of cSN-KBLV in the mouse model, naïve mice 
that succumbed to disease were evaluated by histopathology and immunohistochemistry. 
Infection of naïve mice with cSN-KBLV via the ic route resulted in mild to moderate, mul-
tifocal, neuronal necrosis in the cerebral cortex, thalamic (Figure 7A,B), and hippocampal 
Figure 6. Assessment of serological status in mice following vaccination and challenge. The cSN-
KBLV-challenged mice were serologically assessed against CVS and cSN-KBLV using FAVN and
modified FAVN assays. Dotted line represents 0.5 IU/mL neutralisation cut-off dictated by OIE
ser against CVS. Each symbol is presentative of o e animal. Scale is logarithmic. Asterisks
indicate sig ificant diff rences between the groups calculated using an o dinary two-way ANOVA
and Tukey’s multiple comparisons tests (*** p < 0.001; ns is not significant).
For the va cinated group, all surviving mice developed neutral sing antibody itres.
In the standard FAVN against CVS, sera showed neutralising antibody itres ranging from
1/243 to 1/59049. In the modified FAVN against cSN-KBLV, sera showed le s variab lity
with neutralising antibody titres ranging fro 1 729 to 1/34092. On average, however, the
titre of neutralising antibodies agai st - ere not significantly different.
When comparing the serology post-challenge to that following vaccination and prior
to challe ge (using the standard FAVN), t e titre of neutralising a tibodies in the vaccinated
group increased 50-fold from an average reciprocal titre of 1/284 to 1/14400 (Figures 5 and 6).
Interestingly, the one mouse that succumbed to infection on day 13 post-infection
showed high reciprocal titres of 1/1262 against CVS and 1/2187 against cSN-KBLV (as
indicated by H in both Figures 5A and 6). Despite this, sera from the vaccinated group
show a statically significant difference in neutralising antibody titres against CVS and
cSN-KBLV than the sera derived from the mock-vaccinated group (p < 0.001).
3.4.3. Histopathology and Immunohistochemistry
Of the mice that succumbed to cSN-KBLV, two were tested on the FAT and were
positive for viral antigen. In contrast, of the mice that were vaccinated and survived
challenge with cSN-KBLV, two were tested on the FAT and were all negative (data not
shown). To demonstrate the pathogenicity of cSN-KBLV in the mouse model, naïve mice
that succumbed to disease were evaluated by histopathology and immunohistochemistry.
Infection of naïve mice with cSN-KBLV via the ic route resulted in mild to moderate, multi-
focal, neuronal necrosis in the cerebral cortex, thalamic (Figure 7A,B), and hippocampal
regions (Figure 7C,D) of the forebrain with the association of high levels of viral antigen.
Moderate to minimal amounts of virus antigen were also present multifocally within the
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neuroparenchyma of the thalamus, cerebellum, and brain stem, and rare antigen labelling
was detected in neuronal cell bodies within the spinal cord, but histological changes were
not present in these areas.
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3.4.4. Real-Time RT-PCR 
RNA extracts from the brains of two mice from each vaccine group were evaluated 
via SYBR real-time RT-PCR assay (Table 2). The mouse group showing the lowest mean 
Ct value, 19.05 ± 0.10 and 19.37 ± 0.11, were the mice that succumbed to clinical disease in 
the cSN-KBLV-mock-vaccinated group, therefore indicating that this group had much 
higher viral RNA levels in the brain. The survivors of the vaccinated mouse group showed 
Figure 7. Histopathology and immunohistochemistry (IHC) against rabie nucleoprotein (N) on
cSN-KBLV-infected and uninfected mouse brains. (A,B) A cSN-KBLV ic challenged mouse brain.
Areas of neuronal necrosis with pyknotic nuclei and karyorrhectic cellular debris (outlined with
black dashed-line box) observed in the thalamic region adjacent to the third ventricle (left, H&E
stain) and serial-stained sections for N protein revealed abundant intralesional virus antigens (right,
IHC, white dashed line box for regio of interest co-localised with H&E section). (C,D) A cSN-KBLV
IC-challenged mouse brain. Areas of neuro al necrosis characterised by red, angular and shrunken
neuron (outlined with dashe -line box) in the hippocampus (left, H&E) where IHC-stain d serial
tissue section revealed abundant intralesional virus antigens (right, IHC). (E,F) Negative control.
Representative sections showing no histological changes or virus antigens in the hippocampus.
Images taken at 200x magnification. Insets show digitally magnified region of interest.
3.4.4. Real-Time RT-PCR
RNA extracts from the brains of two mice from each vaccine group were evaluated
via SYBR real-time RT-PCR assay (Table 2). The mouse group showing the lowest mean
Ct value, 19.05 ± 0.10 and 19.37 ± 0.11, were the mice that succumbed to clinical disease
in the cSN-KBLV-mock-vaccinated group, therefore indicating that this group had much
higher viral RNA levels in the brain. The survivors of the vaccinated mouse group showed
the highest mean Ct values with Ct values of 33.14 ± 0.53 and 36.06 ± 0.55, indicating
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that whilst clinical disease did not develop and FAT/IHC were negative, negligible viral
RNA loads were still present in the brain at the time of termination. Based on the CVS
cDNA standard curve, the cSN-KBLV-mock-vaccinated mouse group showed high copy
numbers per gram (g) with 1.07 × 106 copies/g and 8.53 × 105 copies/g and the cSN-
KBLV-vaccinated mice showed either an unquantifiable copy number or low copy number
at 2.07 × 101 copies/g (Figure 8).
Table 2. Post-mortem molecular testing on the brains of two mice from each group.
Mouse Group
SYBR Real-Time RT-PCR Assay
Lyssavirus Nucleoprotein β-Actin
Ct-Value Mean ± SD Ct-Value Mean ± SD
cSN-KBLV-vaccinated
33.14 ± 0.53 23.23 ± 0.11
36.06 ± 0.55 23.87 ± 0.12
cSN-KBLV-mock-vaccinated
19.37 ± 0.11 21.93 ± 0.08
19.03 ± 0.10 21.82 ± 0.14
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4. Discussion 
Rabies, caused by lyssaviruses, remains a neglected tropical disease despite being a 
serious threat to human and animal health globally. For lyssaviruses, the zoonotic threat 
from bats exists and, alongside the emergence of other bat-borne zoonoses, has been 
heightened due to the ongoing encroachment of humans into more remote regions/eco-
systems. Though the current rabies vaccines confer protection against phylogroup I 
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4. Discussion
Rabies, caused by lyss viruses, remains a neglected t opic l disea e d spite being a
serious threat to human and animal ealth globally. For lyssaviruses, the zoonotic threat
from bats exists and, alongside the emergence of other bat-borne zoon s s, has been height-
ened due to the ongoing encroachment of humans into more remote re io s/ecosystems.
Though the current rabies vaccines confer protection against phylogroup I lyssaviruses,
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the discovery of novel lyssaviruses warrants investigation into vaccine efficacy as infection
with lyssaviruses still results in a clinically incurable encephalitis.
KBLV has not been successfully isolated, nor has it been formally classified within
the lyssavirus genus as a virus species despite being genetically related to other members
of the genus. However, the availability of the KBLV genome enabled the synthesis of the
recombinant virus expressing KBLV-G. In this study, the rescued virus was able to grow in
both in vitro and in vivo conditions, demonstrating that the cSN backbone proteins were
able to interact with the heterologous KBLV-G despite relatively low amino acid identity [4].
This further enabled in vitro cross-neutralisation assays and in vivo vaccination-challenge
studies using the recombinant cSN-KBLV virus.
Growth kinetic assessment of this virus revealed that despite a successful virus rescue,
endpoint titres achieved were significantly different with cSN-KBLV reaching a lower final
titre compared to the parent cSN virus (Figure 1). However, the titre achieved was still
higher than titres achieved in previous studies whereby more divergent glycoproteins were
introduced into the same cSN backbone [31]. Decreased viral fitness of cSN-KBLV may be
a result of cSN being more adapted to cell culture or a result of the parent virus (KBLV)
being less able to replicate in cell culture models than the recombinant virus. This cannot
be assessed as a wildtype virus isolate does not exist, although similar examples have been
proposed previously. Certainly, wildtype EBLV-1 and -2 isolates grew to a lower titre than
the recombinant cSN-EBLVs (referred to as cSN-1 and cSN-2), indicating that the low titres
observed were not a result of the G-dependent processes such as receptor binding and
viral entry but rather viral replication and assembly [30]. In a similar study, cSN expressing
IKOV-G and WCBV-G have been shown to grow to viral titres around 105–106, almost 2
log10 lower than cSN-KBLV [31].
For the antigenic assessment of responses to viral glycoproteins in the absence of
a wildtype isolate, cSN-KBLV was used. Previous studies and the data presented here
reiterate that the viral G is the dominant target for neutralising antibodies and underscores
the utility of recombinant vaccines for assessment where wildtype viruses are unavail-
able [30]. To assess the antigenicity of the KBLV-G protein, a mFAVN was undertaken
with a panel of sera specific to different lyssavirus glycoproteins. Previous phylogenetic
assessment determined that KBLV would be classified within phylogroup I given the nu-
cleotide homology of 81%, 79.7%, 79.5%, and 79.4% with KHUV, ARAV, BBLV, and EBLV-2
N proteins, respectively [27]. It was concluded, following the analysis of the whole genome
sequence in a second study, that KBLV is genetically most closely related to EBLV-2, KHUV,
and BBLV [4]. In the neutralisation assays performed in this study, cSN-KBLV grouped
within phylogroup I based on reactivity with phylogroup-specific sera with EBLV-1, BBLV,
and EBLV-2-specific sera exhibited the highest titres of neutralising antibodies against
cSN-KBLV (Figure 3).
Additionally, antigenic cartography was also used to quantitatively analyse anti-
genic data. Antigenic cartography involves geometric interpretation of binding assay
data by assigning each antigen and serum a point on a 3D map such that the distance
between the antigen and antiserum directly corresponds to the reciprocal titres in the
cross-neutralisation assay [37]. Due to the extensive cross-neutralisation between phy-
logroup I species and the novel lyssavirus, cSN-KBLV, the location of these antigens on
the map was fixed by multiple measurements to other antigens/antisera. Consequently,
the resolution of the antigenic maps can be greater than the mFAVN assay resolution [53].
On the antigenic map, cSN-KBLV was closest to cSN, ARAV, IRKV, and EBLV-2 with anti-
genic distances of 1.00 AU, 1.21 AU, 1.45 AU, and 1.65 AU, respectively (Figure 4). These
distances, however, must be interpreted with caution as the resolution of these antigenic
maps in the average prediction error has been previously determined to be 1.22 (SE, 0.17)
antigenic units in 3D [37].
Whilst EBLV-1-specific sera were most able to neutralise cSN-KBLV, being more potent
than sera raised against EBLV-2, BBLV, and KHUV, this phenomenon was not visually
translated in the antigenic maps with EBLV-1 showing an antigenic distance of 2.68 AU
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from cSN-KBLV. Interestingly, cSN was antigenically distinct from RABV and CVS; this
conflicts with the findings of previous studies where RABV strains were indistinguishable
from cSN and ABLV [30,37]. However, a single wildtype RABV was used in this study
(RV437) and further assessment against a panel of RABVs would be needed to reliably infer
antigenic differences between KBLV and circulating street RABV strains. In addition, the
inclusion of additional phylogroup I-specific sera in this study may have identified distinct
antigenic differences between cSN, RABV, ABLV, and CVS. CVS and RABV appear to be
antigenically distant in this study and a previous study [37], indicating antigenic divergence
between street RABV strains and CVS regularly used in diagnostic assays. Furthermore,
the use of serological data to measure antigenic differences in cross-neutralisation assays is
limited by paradoxes or irregularities in the data, such as individual variations between
sera raised against the same antigen or the difficulty of absolute quantification of sera
raised against different isolates for different lyssavirus species [37].
Due to the close antigenic and genetic relationship to phylogroup I, specifically EBLV-
2, EBLV-1, and BBLV, it was predicted that existing rabies vaccines would be able to afford
protection against the KBLV [27]. It was reported that rabies vaccines protect against BBLV
in vivo with an antibody titre of ≥10 IU/mL, suggested through in vivo murine studies as
being required for protection, and EBLV-1 and EBLV-2 in vitro analyses have suggested that
titres ≥4.5 IU/mL are required for neutralisation [18,36]. Additionally, in a previous study
investigating KBLV, sera from human vaccinees could neutralise KBLV-G pseudotyped
RABV particles, however, the sera exhibited a 1.8-fold lower titre of neutralising antibodies
against KBLV than against CVS [4].
In the present study, in vitro neutralisation assays demonstrated that an antibody titre
of 1.0 IU/mL of OIE sera or 2.5 IU/mL of WHO sera were sufficient for neutralisation of
cSN-KBLV above the serological cut-off (Figure 2). In comparison to CVS, OIE standard
sera showed 1.1-fold lower neutralisation activity against cSN-KBLV. The difference in the
neutralising antibody titres against cSN and cSN-KBLV confirms that G is the dominant
target for neutralising antibodies. These values, however, predict the antibody titre required
for protection in vivo when using a standard challenge dose of 100 TCID50/50 µL.
Indeed, the in vivo vaccination-challenge experiments revealed that VeroRab, a com-
mercially available rabies vaccine, afforded almost complete protection against intracranial
challenge of cSN-KBLV (Figure 5B). One vaccinated mouse succumbed to infection at
day 13 but interestingly demonstrated the lowest post-vaccination antibody response as
assessed via FAVN at 0.87 IU/mL (Figure 5A). Whilst above the cut-off 0.5 IU/mL value,
the nature of the “severe” virus challenge through the introduction of the virus intracra-
nially may have been too invasive to prevent productive infection in this single animal.
Regardless, with this sample size we can only speculate that for protection against KBLV
a higher neutralising antibody titre may be needed than that required to give complete
protection against RABV in this in vivo model, in which all mice with antibody titres above
1.5 IU/mL survived ic challenge [18,36,54]. Future work with larger sample sizes would
need to be performed to address this conclusively.
Following in vivo assessment, post-mortem analyses revealed that, based on two
mice from each group, the vaccinated mice that survived to the end of the experiment (22
days, n = 11/12) were negative for lyssavirus antigen in the brain by the gold standard
FAT method but very low levels of viral RNA copies could be detected in the brain
using SYBR real-time RT-PCR. The lethal outcome of infection with wildtype RABV likely
involves multiple mechanisms whereby viral infection drives either evasion or delay of host-
immune mechanisms [55]. Whilst undefined, it is likely that the RNA detected is remnant
noninfectious viral RNA from the original infection, a phenomenon reported previously
in survival from RABV challenge in the murine model [56]. The mock-vaccinated mice
succumbed to infection and the two mice tested in this group were positive for lyssavirus
antigen both in FAT and IHC assays. Further, mice that developed clinical disease had high
levels of viral RNA in the brain, and the majority remained seronegative with only very
low levels of neutralising antibodies being detected (Table 2, Figures 6 and 8).
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Serological comparisons between the mock-vaccinated group and the vaccinated
group revealed a significant difference in serological titre in both the challenge virus and
vaccine virus (Figure 6). Additionally, serological comparison between the vaccinated
mice post-vaccination and the same mice post-challenge revealed a 50-fold increase in
neutralising antibody titre (Figures 5A and 6). These findings are consistent with the
hypothesis that the vaccinated mice mount a successful humoral immune response to
facilitate the clearance of infection earlier than the mock-vaccinated controls, leading to
low viral RNA levels in the brain by the end of the experiment [57,58]. In addition to
humoral immunity, whilst poorly defined, it is likely that the cellular immune response
plays an important role in viral clearance in the CNS [58,59]. Certainly, previous studies
have demonstrated enhanced innate immune responses following rabies vaccination,
including host responses linked with elevated BBB permeability, which enables immune
cell infiltration of the CNS [59,60].
In conclusion, a recombinant cSN-KBLV virus has been generated that has been used
to demonstrate the efficacy of human rabies vaccines to protect against KBLV using the
recombinant virus as a surrogate both in vitro and in vivo. Whilst genetically KBLV G
is most closely related to that of EBLV-2, BBLV, KHUV, and EBLV-1, cross-neutralisation
assays revealed that EBLV-1, BBLV, and EBLV-2 lyssavirus-specific sera showed the highest
neutralising antibodies against cSN-KBLV and antigenic map data revealed that cSN-KBLV
clusters with cSN, ARAV, EBLV-2, and IRKV. Furthermore, a neutralising antibody titre
of 1.5 IU/mL or above was required for the protection in a murine model. As novel
lyssaviruses continue to be described, contemporary assessment of vaccine protection and
evaluation of both genetic and antigenic traits is necessary for the understanding of disease
mitigation strategy.
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